Status:
COMPLETED
Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
UCB Pharma
Conditions:
Memory Loss Associated With Corticosteroid Use
Manic State Associated With Corticosteroid Use
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this research is to determine whether the memory impairment and manic symptoms (feelings of agitation, overexcitement or hyperactivity) typically seen in those on corticosteroid therapy...
Eligibility Criteria
Inclusion
- Age 18-65 years
- Scheduled to receive a corticosteroid "burst" of at least 10 mg of prednisone equivalents and for at least 5 days duration
- English- or Spanish-speaking
Exclusion
- History of allergic reaction or other contraindication to levetiracetam therapy
- Other unstable medical conditions (e.g. recent myocardial infarction, renal failure, diabetes with poor glycemic control)
- Pregnant or nursing women
- History of mental retardation, dementia or other severe cognitive disorders
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00223223
Start Date
February 1 2005
End Date
November 1 2005
Last Update
August 3 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75235